Search Results - "Bergenstal, Richard M."

Glycemic Variability and Diabetes Complications: Does It Matter? Simply Put, There Are Better Glycemic Markers by Bergenstal, Richard M

“…There is no argument that improving mean levels of glycemic control as judged by assays for glycated hemoglobin (HbA(1c)) reduces the risks of microvascular…”
Get full text

Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials by Beck, Roy W, Bergenstal, Richard M, Riddlesworth, Tonya D, Kollman, Craig, Li, Zhaomian, Brown, Adam S, Close, Kelly L

“…This study evaluated the association of time in range (TIR) of 70-180 mg/dL (3.9-10 mmol/L) with the development or progression of retinopathy and development…”
Get full text

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes by Inzucchi, Silvio E, Bergenstal, Richard M, Buse, John B, Diamant, Michaela, Ferrannini, Ele, Nauck, Michael, Peters, Anne L, Tsapas, Apostolos, Wender, Richard, Matthews, David R

“…In 2012, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a position statement on the management…”
Get full text

Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia by Bergenstal, Richard M, Klonoff, David C, Garg, Satish K, Bode, Bruce W, Meredith, Melissa, Slover, Robert H, Ahmann, Andrew J, Welsh, John B, Lee, Scott W, Kaufman, Francine R

“…In this study involving patients with type 1 diabetes, sensor-augmented insulin-pump therapy plus automated insulin suspension when glucose dropped below 70 mg…”
Get full text

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry by Miller, Kellee M, Foster, Nicole C, Beck, Roy W, Bergenstal, Richard M, DuBose, Stephanie N, DiMeglio, Linda A, Maahs, David M, Tamborlane, William V

“…To examine the overall state of metabolic control and current use of advanced diabetes technologies in the U.S., we report recent data collected on individuals…”
Get full text

The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c by Beck, Roy W., Bergenstal, Richard M., Cheng, Peiyao, Kollman, Craig, Carlson, Anders L., Johnson, Mary L., Rodbard, David

“…Background: As the use of continuous glucose monitoring (CGM) increases, there is a need to better understand key metrics of time in range 70-180 mg/dL…”
Get full text

Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring by Bergenstal, Richard M, Beck, Roy W, Close, Kelly L, Grunberger, George, Sacks, David B, Kowalski, Aaron, Brown, Adam S, Heinemann, Lutz, Aleppo, Grazia, Ryan, Donna B, Riddlesworth, Tonya D, Cefalu, William T

“…While A1C is well established as an important risk marker for diabetes complications, with the increasing use of continuous glucose monitoring (CGM) to help…”
Get full text

International Consensus on Use of Continuous Glucose Monitoring by Danne, Thomas, Nimri, Revital, Battelino, Tadej, Bergenstal, Richard M, Close, Kelly L, DeVries, J Hans, Garg, Satish, Heinemann, Lutz, Hirsch, Irl, Amiel, Stephanie A, Beck, Roy, Bosi, Emanuele, Buckingham, Bruce, Cobelli, Claudio, Dassau, Eyal, Doyle, 3rd, Francis J, Heller, Simon, Hovorka, Roman, Jia, Weiping, Jones, Tim, Kordonouri, Olga, Kovatchev, Boris, Kowalski, Aaron, Laffel, Lori, Maahs, David, Murphy, Helen R, Nørgaard, Kirsten, Parkin, Christopher G, Renard, Eric, Saboo, Banshi, Scharf, Mauro, Tamborlane, William V, Weinzimer, Stuart A, Phillip, Moshe

“…Measurement of glycated hemoglobin (HbA ) has been the traditional method for assessing glycemic control. However, it does not reflect intra- and interday…”
Get full text

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes by Marso, Steven P, Daniels, Gilbert H, Brown-Frandsen, Kirstine, Kristensen, Peter, Mann, Johannes F.E, Nauck, Michael A, Nissen, Steven E, Pocock, Stuart, Poulter, Neil R, Ravn, Lasse S, Steinberg, William M, Stockner, Mette, Zinman, Bernard, Bergenstal, Richard M, Buse, John B

“…Patients with type 2 diabetes and high cardiovascular risk were assigned to receive either the glucagon-like peptide 1 analogue liraglutide or placebo. The…”
Get full text

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial by Aroda, Vanita R, Rosenstock, Julio, Wysham, Carol, Unger, Jeffrey, Bellido, Diego, González-Gálvez, Guillermo, Takami, Akane, Guo, Hailing, Niemoeller, Elisabeth, Souhami, Elisabeth, Bergenstal, Richard M

“…This study was conducted to demonstrate the efficacy and safety of LixiLan (iGlarLixi), a novel, titratable, fixed-ratio combination of insulin glargine…”
Get full text

Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group by Fleming, G. Alexander, Petrie, John R., Bergenstal, Richard M., Holl, Reinhard W., Peters, Anne L., Heinemann, Lutz

“…Digital health technology, especially digital and health applications (‘apps’), have been developing rapidly to help people manage their diabetes. Numerous…”
Get full text

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1) by Russell-Jones, David, Bode, Bruce W, De Block, Christophe, Franek, Edward, Heller, Simon R, Mathieu, Chantal, Philis-Tsimikas, Athena, Rose, Ludger, Woo, Vincent C, Østerskov, Anne Birk, Graungaard, Tina, Bergenstal, Richard M

“…This multicenter, treat-to-target, phase 3 trial evaluated the efficacy and safety of fast-acting insulin aspart (faster aspart) versus conventional insulin…”
Get full text

Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial by Monteiro, Pedro, Bergenstal, Richard M, Toural, Elvira, Inzucchi, Silvio E, Zinman, Bernard, Hantel, Stefan, Kiš, Sanja Giljanovic, Kaspers, Stefan, George, Jyothis T, Fitchett, David

“…Abstract Objective The risks of cardio-renal complications of diabetes increase with age. In the EMPA-REG OUTCOME® trial, empagliflozin reduced cardiovascular…”
Get full text

Evidence of a Strong Association Between Frequency of Self-Monitoring of Blood Glucose and Hemoglobin A1c Levels in T1D Exchange Clinic Registry Participants by MILLER, Kellee M, BECK, Roy W, BERGENSTAL, Richard M, GOLAND, Robin S, HALLER, Michael J, MCGILL, Janet B, RODRIGUEZ, Henry, SIMMONS, Jill H, HIRSCH, Irl B

“…Despite substantial evidence of the benefit of frequent self-monitoring of blood glucose (SMBG) in type 1 diabetes, certain insurers limit the number of test…”
Get full text

Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels by Bergenstal, Richard M, Gal, Robin L, Connor, Crystal G, Gubitosi-Klug, Rose, Kruger, Davida, Olson, Beth A, Willi, Steven M, Aleppo, Grazia, Weinstock, Ruth S, Wood, Jamie, Rickels, Michael, DiMeglio, Linda A, Bethin, Kathleen E, Marcovina, Santica, Tassopoulos, Andreana, Lee, Sooji, Massaro, Elaine, Bzdick, Suzan, Ichihara, Brian, Markmann, Eileen, McGuigan, Paul, Woerner, Stephanie, Ecker, Michelle, Beck, Roy W

“…Debate exists as to whether the higher hemoglobin A1c (HbA1c) levels observed in black persons than in white persons are due to worse glycemic control or…”
Get full text

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial by Bergenstal, Richard M, Dr, Wysham, Carol, MD, MacConell, Leigh, PhD, Malloy, Jaret, PhD, Walsh, Brandon, PhD, Yan, Ping, PhD, Wilhelm, Ken, MD, Malone, Jim, MD, Porter, Lisa E, MD

“…Summary Background Most patients with type 2 diabetes begin pharmacotherapy with metformin, but eventually need additional treatment. We assessed the safety…”
Get full text

The Effect of Treatment of Obstructive Sleep Apnea on Glycemic Control in Type 2 Diabetes by Shaw, Jonathan E, Punjabi, Naresh M, Naughton, Matthew T, Willes, Leslee, Bergenstal, Richard M, Cistulli, Peter A, Fulcher, Greg R, Richards, Glenn N, Zimmet, Paul Z

“…There is uncertainty about the effects of treating obstructive sleep apnea on glycemic control in patients with type 2 diabetes. To determine whether treatment…”
Get full text

Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry by Wong, Jenise C, Foster, Nicole C, Maahs, David M, Raghinaru, Dan, Bergenstal, Richard M, Ahmann, Andrew J, Peters, Anne L, Bode, Bruce W, Aleppo, Grazia, Hirsch, Irl B, Kleis, Lora, Chase, H Peter, DuBose, Stephanie N, Miller, Kellee M, Beck, Roy W, Adi, Saleh

“…To assess the frequency of continuous glucose monitoring (CGM) device use, factors associated with its use, and the relationship of CGM with diabetes outcomes…”
Get full text

Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial by Marso, Steven P., MD, Poulter, Neil R., FRCP, Nissen, Steven E., MD, Nauck, Michael A., MD, Zinman, Bernard, MD, Daniels, Gilbert H., MD, Pocock, Stuart, PhD, Steinberg, William M., MD, Bergenstal, Richard M., MD, Mann, Johannes F.E., MD, Ravn, Lasse Steen, MD, PhD, Frandsen, Kirstine Brown, MD, Moses, Alan C., MD, Buse, John B., MD, PhD

“…Background Diabetes is a multisystem disorder associated with a nearly twofold excess risk for a broad range of adverse cardiovascular outcomes including…”
Get full text

Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE by Bergenstal, Richard M, Hachmann-Nielsen, Elise, Kvist, Kajsa, Peters, Anne L, Tarp, Jens Magelund, Buse, John B

“…Time spent in glycemic target range (time in range [TIR]; plasma glucose 70-180 mg/dL [3.9-10.0 mmol/L]) as a surrogate endpoint for long-term diabetes-related…”
Get more information